FundingWatcher
Home / Startups / Top biotech startups / Biotech startups that raised Series B / Biotech startups that raised Series B in the United States

Biotech startups that raised Series B in the United States

Updated 16 Nov 2026

Reset
Biotech startups that raised Series B in the United States
One-time CSV
  • 682 funded companies, 602 with a website
  • Last round, amount, date, total raised and investors
  • CRM-ready CSV, 18 columns
  • Download right after payment
With founder contacts
Compiled to order
  • The full startup CSV, plus founders and executives
  • Up to 2 founders or CEOs per company, compiled to order
  • Name, job title and LinkedIn URL where found
  • Verified direct email per person
  • Startup CSV at once, contacts CSV by mail within 24 hours
Download right after paymentFree 10-row sampleSecure checkout by Stripe

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

startups-biotech--series-b~united-states.csv682 rows × 18 columns
CompanyCityLast roundAmountDate
Prolific MachinesEmeryvilleSeries B$50.0M2026-10-14
Multiply LabsSan FranciscoSeries B$75.0M2026-10-06
Tiny HealthAustinSeries B$33.0M2026-09-29
EvvyNew YorkSeries B$40.0M2026-09-15
Moonwalk BiosciencesSouth San FranciscoSeries B$70.0M2026-09-08
Superluminal MedicinesBostonSeries B$65.5M2026-09-03
N-Power MedicineRedwood CitySeries B$32.0M2026-09-01
SimnovaCambridgeSeries B$59.3M2026-08-18

8 rows of the CSV in 5 of its 18 columns.

682
Startups
$51.5B
Total raised
82
Funded in the last 12 months
$5.5B
Raised in the last 12 months

Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.

Newest rounds

30 of 682
30 rows
Company What they do Sector City Last round Amount Date Total raised Investors Employees Founded
Prolific Machines Prolific Machines develops light-controlled gene expression systems for producing therapeutics. Artificial intelligence Emeryville Series B $50.0M 2026-10-14 $147.0M SOSV, Mayfield Fund, SOSV SF & NY (Fka IndieBio) +2 51 to 100 2020
Multiply Labs Multiply Labs builds robotic systems that automate biologics manufacturing. Artificial intelligence San Francisco Series B $75.0M 2026-10-06 $97.7M Y Combinator, Founders Fund, Garage Capital +2 11 to 50 2016
Tiny Health Tiny Health offers at-home microbiome testing and health insights for babies, children, adults, and pregnant people. Biotech Austin Series B $33.0M 2026-09-29 $46.0M TheVentureCity, Next Coast Ventures, Spero Ventures +2 11 to 50 2020
Evvy Evvy offers an AI-driven precision medicine platform focused on women's health. Artificial intelligence New York Series B $40.0M 2026-09-15 $59.0M General Catalyst, BoxGroup, Left Lane Capital +2 11 to 50 2021
Moonwalk Biosciences Moonwalk Biosciences develops precision epigenetic medications through its genomic medicine platform. Artificial intelligence South San Francisco Series B $70.0M 2026-09-08 $127.0M Google Ventures, Khosla Ventures, ARCH Venture Partners +2 11 to 50 2022
Superluminal Medicines Superluminal Medicines develops small-molecule therapeutics by combining AI, biology, and chemistry. Artificial intelligence Boston Series B $65.5M 2026-09-03 $223.5M Insight Partners, RA Capital Management, NVentures 11 to 50 2022
N-Power Medicine N-Power Medicine is a biotechnology company that uses AI to offer clinical research and drug development services. Artificial intelligence Redwood City Series B $32.0M 2026-09-01 $104.0M Merck Global Health Innovation Fund 101 to 250 2021
Simnova Simnova Biotherapeutics develops CAR-based cell therapies for treating cancer. Biotech Cambridge Series B $59.3M 2026-08-18 $87.2M Oriza Seed Capital (Oriza Yuandian), Youshan Capital, PagodaTree Partners +1 51 to 100 2019
InduPro InduPro develops proximity-based protein therapeutics that modulate cell-surface protein interactions to treat disease. Biotech Seattle Series B $77.0M 2026-08-12 $162.0M Euclidean Capital, The Column Group, Vida Ventures +1 51 to 100 2022
Aureka Biotechnologies Aureka Biotechnologies uses AI to discover protein therapeutics and antibody treatments. Artificial intelligence Laguna Hills Series B $100.0M 2026-08-10 $168.4M K2VC, NRL Capital 11 to 50 2023
Theradaptive Theradaptive develops protein therapeutics for spine, orthopedics, and targeted immuno-oncology. Biotech Frederick Series B $36.2M 2026-08-04 $71.0M Maryland Stem Cell Research Fund (MSCRF) 11 to 50 2016
Claris Biotherapeutics Claris Biotherapeutics develops biologic therapies for corneal diseases and ocular surface disorders. Biotech Jersey City Series B $118.0M 2026-07-28 $225.1M RA Capital Management, Novo Holdings, Janus Henderson Investors +1 1 to 10 2018
Kuehnle Agrosystems Kuehnle Agrosystems develops plant-based systems to produce biologically active compounds through biotech research. Biotech Honolulu Series B $3.0M 2026-07-06 $11.8M S2G Investments, Cavallo Ventures, Aqua Spark +2 1 to 10 2007
Cour Pharmaceuticals Development Cour Pharmaceuticals Development develops nanoparticle technology to reset immune systems in multiple sclerosis patients. Biotech Skokie Series B $50.0M 2026-06-18 $185.5M Alpha Wave Global, Bristol-Myers Squibb, Alpha Wave Ventures +2 51 to 100 2015
Elemental Machines Elemental Machines provides data-driven insights to improve research, laboratory operations, and manufacturing outcomes. Artificial intelligence Cambridge Series B $5.7M 2026-05-27 $66.5M Founders Fund, Tau Ventures, Rock Health Capital +2 11 to 50 2015
LTZ Therapeutics LTZ Therapeutics develops novel immunotherapies for cancer and other diseases with unmet clinical needs. Biotech San Francisco Series B $38.0M 2026-05-06 $125.0M Qiming Venture Partners, Shunwei Capital, K2VC +1 11 to 50 2022
Kytopen Kytopen develops genome engineering platforms for cell therapy research and manufacturing. Biotech Cambridge Series B $1.6M 2026-04-07 $39.1M National Science Foundation, MassVentures, Alexandria Venture Investments +1 11 to 50 2017
Ambrosia Biosciences Ambrosia Biosciences provides drug development services for small molecule therapies targeting obesity and metabolic disorders. Biotech Boulder Series B $100.0M 2026-03-31 $141.0M Boulder Ventures, Biotechnology Value Fund 11 to 50 2024
Unnatural Products Unnatural Products is a biotech company that develops macrocyclic peptide drug therapies. Artificial intelligence Santa Cruz Series B $45.0M 2026-03-16 $83.0M Abstract, Better Ventures, Artis Ventures +2 11 to 50 2017
Atavistik Bio Atavistik Bio develops precision allosteric small molecules to treat metabolic diseases and cancer. Biotech Cambridge Series B $40.0M 2026-03-05 $260.0M Lux Capital, The Column Group, Nextech Invest 11 to 50 2021
BreezeBio BreezeBio is a biotechnology company that develops genetic therapies using non-viral delivery to clinically important tissues. Artificial intelligence Brisbane Series B $60.0M 2026-02-25 $127.7M Sequoia Capital, National Science Foundation, Qiming Venture Partners +1 51 to 100 2016
Mirador Therapeutics Mirador Therapeutics develops precision medicines for immune-mediated diseases. Biotech San Diego Series B $250.0M 2026-01-12 $730.0M OrbiMed, Fidelity, ARCH Venture Partners +1 11 to 50 2024
Precede Biosciences Precede Biosciences develops blood-based tests that reveal disease-defining transcriptional biology. Biotech Boston Series B $63.5M 2026-01-12 $140.5M Bristol-Myers Squibb, Lilly Asia Ventures, 5AM Ventures +2 11 to 50 2005
Diagonal Therapeutics Diagonal Therapeutics develops targeted therapies for cancer and genetic diseases. Biotech Watertown Series B $125.0M 2026-01-08 $253.0M Lightspeed Venture Partners, RA Capital Management, Atlas Venture +1 11 to 50 2022
Nocion Therapeutics Nocion Therapeutics develops pharmaceuticals to treat conditions arising from neurogenic inflammation. Biotech Cambridge Series B $23.0M 2026-01-07 $134.0M Canaan Partners, F-Prime, OUP (Osage University Partners) +2 11 to 50 2017
Myrtelle Myrtelle is a gene therapy company that runs clinical trials for rare monogenetic disorders. Biotech Wakefield Series B $30.5M 2025-12-23 $57.6M Panacea Venture 11 to 50 2020
Manifold Manifold provides machine learning tools that analyze operational data to support industrial and energy decisions. Artificial intelligence Newton Series B $18.0M 2025-12-18 $40.5M TQ Ventures, Calibrate Ventures, SK Ventures +1 101 to 250 2016
Aeovian Pharmaceuticals Aeovian Pharmaceuticals develops and commercializes therapeutics for rare and age-related diseases. Biotech San Francisco Series B $55.0M 2025-12-16 $142.0M Sofinnova Investments, venBio Partners, Apollo Health Ventures 1 to 10 2012
Alphyn Biologics Alphyn Biologics develops Multi-Target Therapeutics for treating skin diseases. Biotech Cincinnati Series B $25.0M 2025-12-12 $36.8M Angel Physicians Fund, Serial Stage Venture Partners 1 to 10 2019
BlossomHill Therapeutics BlossomHill Therapeutics is a biopharmaceutical company focused on oncology and autoimmune disorders. Biotech San Diego Series B $84.0M 2025-12-10 $257.0M OrbiMed, Cormorant Asset Management, Vivo Capital +2 11 to 50 2020

Table 1. Biotech startups that raised Series B in the United States: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 682.

Largest rounds

Last 12 months
10 rows
# Company What they do Sector City Last round Amount Date Total raised Investors Employees Founded
1 Mirador Therapeutics Mirador Therapeutics develops precision medicines for immune-mediated diseases. Biotech San Diego Series B $250.0M 2026-01-12 $730.0M OrbiMed, Fidelity, ARCH Venture Partners +1 11 to 50 2024
2 Diagonal Therapeutics Diagonal Therapeutics develops targeted therapies for cancer and genetic diseases. Biotech Watertown Series B $125.0M 2026-01-08 $253.0M Lightspeed Venture Partners, RA Capital Management, Atlas Venture +1 11 to 50 2022
3 Claris Biotherapeutics Claris Biotherapeutics develops biologic therapies for corneal diseases and ocular surface disorders. Biotech Jersey City Series B $118.0M 2026-07-28 $225.1M RA Capital Management, Novo Holdings, Janus Henderson Investors +1 1 to 10 2018
4 Sanegene Bio Sanegene Bio develops an RNAi drug discovery platform aimed at unmet clinical needs. Biotech Woburn Series B $110.0M 2025-12-08 $240.0M Shenzhen Capital Group, Qiming Venture Partners, Northern Light Venture Capital +1 51 to 100 2021
5 Profluent Bio Profluent Bio designs new proteins and gene-editing tools using AI for medicine, agriculture, and science. Artificial intelligence Emeryville Series B $106.0M 2025-11-19 $150.0M Insight Partners, Spark Capital, AIX Ventures +1 11 to 50 2022
6 Aureka Biotechnologies Aureka Biotechnologies uses AI to discover protein therapeutics and antibody treatments. Artificial intelligence Laguna Hills Series B $100.0M 2026-08-10 $168.4M K2VC, NRL Capital 11 to 50 2023
7 Ambrosia Biosciences Ambrosia Biosciences provides drug development services for small molecule therapies targeting obesity and metabolic disorders. Biotech Boulder Series B $100.0M 2026-03-31 $141.0M Boulder Ventures, Biotechnology Value Fund 11 to 50 2024
8 BlossomHill Therapeutics BlossomHill Therapeutics is a biopharmaceutical company focused on oncology and autoimmune disorders. Biotech San Diego Series B $84.0M 2025-12-10 $257.0M OrbiMed, Cormorant Asset Management, Vivo Capital +2 11 to 50 2020
9 InduPro InduPro develops proximity-based protein therapeutics that modulate cell-surface protein interactions to treat disease. Biotech Seattle Series B $77.0M 2026-08-12 $162.0M Euclidean Capital, The Column Group, Vida Ventures +1 51 to 100 2022
10 Multiply Labs Multiply Labs builds robotic systems that automate biologics manufacturing. Artificial intelligence San Francisco Series B $75.0M 2026-10-06 $97.7M Y Combinator, Founders Fund, Garage Capital +2 11 to 50 2016

Table 2. Biotech startups that raised Series B in the United States: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most active investors

By companies backed
#InvestorTypeLocation CompaniesShare Funded, 12 monthsLatest
1 RA Capital Management Startup incubator Boston, United States 12 2% 3 Superluminal Medicines, Claris Biotherapeutics, Diagonal Therapeutics
2 OrbiMed Private equity firm New York, United States 11 2% 2 Mirador Therapeutics, BlossomHill Therapeutics
3 Google Ventures Corporate venture arm San Francisco, United States 8 1% 1 Moonwalk Biosciences
4 ARCH Venture Partners Venture capital firm Chicago, United States 8 1% 2 Moonwalk Biosciences, Mirador Therapeutics
5 Alexandria Venture Investments Venture capital firm Pasadena, United States 8 1% 1 Kytopen
6 Bristol-Myers Squibb Venture capital firm New York, United States 7 1% 2 Cour Pharmaceuticals Development, Precede Biosciences
7 Alumni Ventures Angel group Manchester, United States 7 1% 1 Sorcero
8 Andreessen Horowitz Venture capital firm Menlo Park, United States 7 1%
9 National Science Foundation Entrepreneurship program Alexandria, United States 6 1% 2 Kytopen, BreezeBio
10 Digitalis Ventures Venture capital firm New York, United States 5 1% 1 Elemental Machines
11 Forbion Capital Partners Private equity firm Naarden, The Netherlands 5 1%
12 Samsara BioCapital Private equity firm Palo Alto, United States 5 1%
13 Alpha Wave Global Private equity firm Miami, United States 4 1% 2 Moonwalk Biosciences, Cour Pharmaceuticals Development
14 Insight Partners Private equity firm New York, United States 4 1% 2 Superluminal Medicines, Profluent Bio
15 Qiming Venture Partners Venture capital firm Shanghai, China 4 1% 3 LTZ Therapeutics, BreezeBio, Sanegene Bio

Table 3. Biotech startups that raised Series B in the United States: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Sectors

SectorsCompaniesShareTotal raised
Health care 609 89% $47.7B
Software 83 12% $6.0B
Artificial intelligence 45 7% $4.2B
Hardware 24 4% $741.4M
Cybersecurity 7 1% $407.4M
Fintech 6 1% $359.3M
Energy 5 1% $142.5M
Commerce 4 1% $149.4M

Table 4. Biotech startups that raised Series B in the United States by sector. Source: FundingWatcher. Data as of 16 November 2026.

Funding stage

Funding stageCompaniesShareMedian last round
Series B 682 100% $26.6M

Table 5. Biotech startups that raised Series B in the United States by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Cities

CitiesCompaniesShare
Cambridge 68 10%
San Diego 53 8%
Boston 40 6%
San Francisco 34 5%
New York 27 4%
Seattle 23 3%
South San Francisco 15 2%
Palo Alto 13 2%
Waltham 13 2%
Houston 12 2%
Durham 10 1%
Watertown 10 1%

Table 6. Biotech startups that raised Series B in the United States by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.

Rounds by month

Rounds by monthCompaniesShareRaised
November 2026 1 1% $41.9M
October 2026 6 7% $545.0M
September 2026 9 11% $284.0M
August 2026 8 10% $556.2M
July 2026 5 6% $253.4M
June 2026 9 11% $1.0B
May 2026 4 5% $192.2M
April 2026 5 6% $270.6M
March 2026 5 6% $351.0M
February 2026 4 5% $221.5M
January 2026 11 13% $801.5M
December 2025 12 15% $700.5M
November 2025 3 4% $207.7M

Table 7. Biotech startups that raised Series B in the United States: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most recent round by year

Most recent round by yearCompaniesShareRaised
2026 67 10% $4.5B
2025 67 10% $4.3B
2024 57 8% $3.7B
2023 52 8% $2.9B
2022 51 7% $2.2B
2021 72 11% $4.4B

Table 8. Biotech startups that raised Series B in the United States by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Founding year

Founding yearCompaniesShare
2023 or later 16 2%
2020 to 2022 89 13%
2015 to 2019 224 33%
2010 to 2014 137 20%
Before 2010 215 32%

Table 9. Biotech startups that raised Series B in the United States by founding year. Source: FundingWatcher. Data as of 16 November 2026.

Team size

Team sizeCompaniesShare
1 to 10 139 21%
11 to 50 349 52%
51 to 100 116 17%
101 to 250 42 6%
251 to 500 7 1%
501 to 1,000 7 1%
1,001 to 5,000 3 0%
5,001 to 10,000 2 0%
10,001 or more 6 1%

Table 10. Biotech startups that raised Series B in the United States by headcount. Source: FundingWatcher. Data as of 16 November 2026.

Method

Sources, fields and exclusions of both files: Method.

Questions

How many biotech startups in the United States whose last round is Series B are on the list?
682, in the file dated 16 November 2026. 82 of them closed their most recent round in the last 12 months.
What does the CSV contain?
One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
How much does the list cost?
$29 one-time for all 682 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $349.
What arrives after payment?
At once: the CSV download link, on the page after payment and by mail.
Can I see rows before buying?
The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
How current is the data?
The file is dated 16 November 2026. The download link serves the current file each time it is opened.

Biotech startups that raised Series B in the United States: 682 rows, CSV, $29 one-time.

At once: the CSV download link, on the page after payment and by mail.

Columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.

With founder contacts: $349 one-time. List CSV right after payment; up to 2 verified founder or CEO emails per company compiled to order within 24 hours.

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

Biotech at other stages in United States

Other sectors that raised Series B in United States

Cite: FundingWatcher, 682 biotech companies in the United States whose most recent round is Series B, 16 November 2026. https://fundingwatcher.com/startups/biotech/series-b/united-states/